saxagliptin
Also known as BMS-477118, BMS 477118, (1S,3S,5S)-2-((2S)-Amino(3-hydroxytricyclo(3.3.1.13,7)dec-1-yl)acetyl)-2-azabicyclo(3.1.0)hexane-3-carbonitrile, saxagliptin anhydrous, Saxagliptin anhydrous
Saxagliptin, sold under the brand name Onglyza, is an oral hypoglycemic (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. Early development was solely by Bristol-Myers Squibb; in 2007 AstraZeneca joined with Bristol-Myers Squibb to co-develop the final compound and collaborate on the marketing of the drug.
~8 min read
Article
9 sectionsContents
- Medical uses
- Adverse effects
- Tolerability
- Pancreatitis and pancreatic cancer
- Production
- Pharmacology
- Licensing
- References
- External links
Saxagliptin, sold under the brand name Onglyza, is an oral hypoglycemic (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. Early development was solely by Bristol-Myers Squibb; in 2007 AstraZeneca joined with Bristol-Myers Squibb to co-develop the final compound and collaborate on the marketing of the drug.
In April 2016, the U.S. FDA added a warning about increased risk of heart failure. This was based on data in an article that concluded "DPP-4 inhibition with saxagliptin did not increase or decrease the rate of ischemic events, though the rate of hospitalization for heart failure was increased. Although saxagliptin improves glycemic control, other approaches are necessary to reduce cardiovascular risk in patients with diabetes."
Connections
Categories
AdamantanesCarboxamidesChemical articles with multiple CAS registry numbersChemical articles with multiple PubChem CIDsChemicals using indexlabelsDipeptidyl peptidase-4 inhibitorsDrugboxes which contain changes to verified fieldsDrugboxes which contain changes to watched fieldsDrug has EMA linkDrugs developed by AstraZenecaDrugs developed by Bristol Myers Squibb